ADC Therapeutics SA reports results for the quarter ended in December - Earnings Summary

ADC Therapeutics SA

03/03/2022 13:41

* ADC Therapeutics SA  ADCT.N  reported a quarterly adjusted
loss
of 45 cents​​ per share for the quarter ended in December. The
mean expectation of seven analysts for the quarter was for a
loss of 86 cents per share.
    * Revenue was $17.01 million​;  analysts expected $16.46
million. 
    * ADC Therapeutics SA's reported EPS for the quarter was a
loss
of 45 cents​.
    * The mean earnings estimate of analysts had fallen by
about 4.7%
in the last three months.​ 
    * In the last 30 days there have been no negative revisions
of
earnings estimates 
    * ADC Therapeutics SA shares had fallen by 19.7% this
quarter.
    * The company reported a quarterly loss of $34.38 million.
    * Wall Street's median 12-month price target for ADC
Therapeutics
SA is $41.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 8 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 

This summary was machine generated March 3 at 01:40 p.m.  ​All
figures in US dollars unless otherwise stated